NCT01171898 2026-02-24
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
Aragon Pharmaceuticals, Inc.
enGene, Inc.
Memorial Sloan Kettering Cancer Center
Fondazione Italiana Linfomi - ETS
Lamassu Bio Inc
AtlasMedx, Incorporated
Children's Hospital of Philadelphia